What are the major global Translational Neuroscience Programs?

Major **Global Brain Initiatives** in Translational Neuroscience

Since 2013, multiple nations have launched large-scale brain research programs totaling over $7 billion in committed funding, each with distinct but complementary translational goals (Richardson, 2017; Grillner et al., 2016). These initiatives span the United States, European Union, Japan, China, Australia, and Korea, and increasingly coordinate through an International Brain Initiative (Richardson, 2017; Grillner et al., 2016; Brose, 2016).

National Brain Initiatives

Program	Country	Key Translational Focus
BRAIN Initiative	United States	Neurotechnology development; circuit-level monitoring of neural activity (Richardson, 2017)
Human Brain Project (HBP)	European Union	ICT-based brain research infrastructure; six cloud platforms for simulation, neurorobotics, and medical informatics (Richardson, 2017)
Brain/MINDS	Japan	Marmoset brain atlas; genetically modified primates for pre-clinical studies; clinical biomarker center (Richardson, 2017)
China Brain Project	China	15-year plan (2016–2030); early diagnosis and intervention of brain disorders; brain-inspired AI (Richardson, 2017)
Korea Brain Initiative	Korea	Multi-scale brain mapping; personalized medicine for neurological disorders (Richardson, 2017)

FIGURE 1 Comparison of major national brain research initiatives

Disease-Focused and Consortia Programs

The **ENIGMA Consortium** unites over 1,400 scientists across 43 countries, operating 50+ working groups that have produced the largest neuroimaging studies to date in schizophrenia, bipolar disorder, major depressive disorder, PTSD, OCD, ADHD, and epilepsy (Thompson et al., 2019). The **Ataxia Global Initiative** connects academic centers, patient advocacy organizations, and industry partners across Europe, the Americas, Asia, and Australia to accelerate clinical trials for hereditary ataxias (Klockgether et al., 2022). The **German Center for Neurodegenerative Diseases (DZNE)** appears as a recurring institutional anchor across multiple translational programs (Klockgether et al., 2022; Thompson et al., 2019).

- **Brain Canada** funds cross-disciplinary research through its Canada Brain Research Fund, treating the brain as a single complex system across neurological disorders (Richardson, 2017).
- The **Australian Brain Alliance** targets neural interface development, lifelong brain health, and brain-inspired computing (Richardson, 2017).
- **NeuroTech Harbor**, a Howard–Johns Hopkins partnership funded by NIH's Blueprint MedTech program, accelerates device development for Alzheimer's, Parkinson's, stroke, and addiction while supporting underrepresented innovators (Hermann et al., 2025).

Infrastructure and Coordination Efforts

The European HBP's successor platform **EBRAINS** provides multinational infrastructure for brain modeling and simulation across borders, exemplified by the eBRAIN-Health initiative (Fekonja et al., 2025). The U.S. NIH has established co-funding agreements with Brain Canada Foundation, the Australian NHMRC, and Denmark's Lundbeck Foundation to support foreign investigators within BRAIN Initiative teams (Grillner et al., 2016). Germany's **Collaborative Research Centers (CRC)** program funds basic-to-translational neuroscience consortia for up to 12 years, such as CRC TRR332 on neutrophil biology bridging multi-omics with clinically relevant disease models (Hermann et al., 2025).

These programs share common goals—unmasking disease pathogenesis, developing biomarkers for early diagnosis, and accelerating therapeutics—while facing persistent translational challenges including high drug attrition rates (~99.6% for AD programs), model standardization gaps, and insufficient interdisciplinary training (Zheng & Chen, 2022; Niziński et al., 2026; Hermann et al., 2025). Neuroethics and equitable access to emerging therapies are increasingly recognized as essential dimensions of global neuroscience coordination (Dere, 2026; Illes & Hannan, 2023).

References

Brose, K. (2016). Global Neuroscience.. *Neuron, 92 3*, 557-558. https://doi.org/10.1016/j.neuron.2016.10.047

Dere, E. (2026). Quo Vadis translational neuroscience?. *Translational Neuroscience, 17.* https://doi.org/10.1515/tnsci-2025-0393

Fekonja, L., Forkel, S. J., Aydogan, D., Lioumis, P., Cacciola, A., Lucas, C. W., Tournier, J.-D., Vergani, F., Ritter, P., Schenk, R., Shams, B., Engelhardt, M., & Picht, T. (2025). Translational network neuroscience: Nine roadblocks and possible solutions. *Network Neuroscience, 9*, 352 - 370. https://doi.org/10.1162/netn_a_00435

Grillner, S., Ip, N., Koch, C., Koroshetz, W., Okano, H., Polachek, M., Poo, M., & Sejnowski, T. (2016). Worldwide initiatives to advance brain research. *Nature neuroscience, 19*, 1118 - 1122. https://doi.org/10.1038/nn.4371

Hermann, D., Bacigaluppi, M., Bassetti, C., Bassotti, G., Boltze, J., Chan, A., Dalkara, T., Dénes, Á., Díez-Tejedor, E., Dodel, R., Doeppner, T., Dzyubenko, E., ElAli, A., Fulop, T., Gerhard, A., Giebel, B., Gronewold, J., Gunzer, M., Heinbockel, T., . . . Zhang, J. (2025). Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation. *Exploration of neuroscience, 4.* https://doi.org/10.37349/en.2025.1006106

Illes, J., & Hannan, A. J. (2023). Synergies of Translational and Transnational Neuroethics for Global Neuroscience. *AJOB Neuroscience, 14*, 400 - 401. https://doi.org/10.1080/21507740.2023.2257165

Klockgether, T., Ashizawa, T., Brais, B., Chuang, R., Durr, A., Fogel, B. L., Greenfield, J., Hagen, S., Jardim, L., Jiang, H., Onodera, O., Pedroso, J., Soong, B., Szmulewicz, D., Graessner, H., & Synofzik, M. (2022). Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective. *Movement Disorders, 37.* https://doi.org/10.1002/mds.29032

Niziński, P., Szalast, K., Makuch-Kocka, A., Paruch-Nosek, K., Ciechanowska, M., & Plech, T. (2026). Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease. *Molecules, 31.* https://doi.org/10.3390/molecules31020320

Richardson, R. (2017). Global Brain Initiatives.. *Neurosurgery, 80 5*, N21-N22. https://doi.org/10.1093/neuros/nyx118

Thompson, P., Jahanshad, N., Ching, C., Salminen, L. E., Thomopoulos, S., Bright, J. K., Baune, B., Bertolín, S., Bralten, J., Bruin, W., Bülow, R., Chen, J., Chye, Y., Dannlowski, U., De Kovel, C. G. F., Donohoe, G., Eyler, L., Faraone, S., Favre, P., . . . Zelman, V. (2019). ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. *Translational Psychiatry, 10*. https://doi.org/10.1038/s41398-020-0705-1

Zheng, J., & Chen, S. (2022). Translational Neurodegeneration in the era of fast growing international brain research. *Translational Neurodegeneration, 11*. https://doi.org/10.1186/s40035-021-00276-9